Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical c...
Leadership
James R. Porter Ph.D.
CEO, President & Director
Alexandra Balcom CPA, M.B.A.
CFO & Treasurer
Deborah Ann Miller J.D., Ph.D.
Chief Legal Officer & Secretary
Darlene Noci
Chief Development Officer
Christopher D. Turner M.D.
Chief Medical Officer
Benjamin Lane Ph.D.
Chief Technical Operations Officer
Henry Pelish Ph.D.
Chief Scientific Officer
Chelcie Lister
Senior Director of Investor Relations & Corporate Communications
John Soglia Ph.D.
Senior Vice President of Translational Development
